Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus
Background The human haptoglobin (Hp) gene is polymorphic with two functional classes of alleles, denoted 1 and 2. We have demonstrated in three longitudinal studies and several cross‐sectional studies that the Hp genotype is an independent risk factor for diabetic vascular disease. These studies ha...
Gespeichert in:
Veröffentlicht in: | Diabetes/metabolism research and reviews 2005-07, Vol.21 (4), p.332-337 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
The human haptoglobin (Hp) gene is polymorphic with two functional classes of alleles, denoted 1 and 2. We have demonstrated in three longitudinal studies and several cross‐sectional studies that the Hp genotype is an independent risk factor for diabetic vascular disease. These studies have presented a compelling argument that diabetic individuals homozygous for the Hp 1 allele are at decreased risk of vascular complications as compared to diabetic individuals with the Hp 2 allele.
Methods
The naturally occurring (wild type) mouse Hp is a class 1 Hp allele. We examined renal hypertrophy in wild‐type mice, Hp knockout mice (Hp 0), and in mice with the Hp 2 allele (Hp 2) with and without diabetes.
Results
In the absence of diabetes, we found that renal hypertrophy was significantly increased in Hp 0 mice and that this could be prevented with vitamin E. There was no difference between wild type and Hp 2 mice with regard to renal hypertrophy in the absence of diabetes. However, in the presence of diabetes, Hp 2 mice demonstrated a significant increase in renal hypertrophy as compared to wild‐type mice.
Conclusions
These results support a direct linkage between diabetic vascular disease and the Hp genotype. These Hp‐modified mice may serve as a platform on which to test a variety of pharmacological agents in order to decrease diabetic vascular disease. Copyright © 2005 John Wiley & Sons, Ltd. |
---|---|
ISSN: | 1520-7552 1520-7560 |
DOI: | 10.1002/dmrr.556 |